ArticleJournal of bioethical inquiry2015
Drug Familiarization and Therapeutic Misconception Via Direct-to-Consumer Information.
Article in Journal of bioethical inquiry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Advertising Alternative Cancer Treatments and Approaches on Meta Social Media Platforms: Content Analysis.JMIR infodemiology · 2023Article
- Digital Therapies (DTx) as New Tools within Physicians' Therapeutic Arsenal: Key Observations to Support their Effective and Responsible Development and Use.Pharmaceutical medicine · 2023Article
- Your robot therapist is not your therapist: understanding the role of AI-powered mental health chatbots.Frontiers in digital health · 2023Article
- Recommendations for the ethical conduct of vaccination awareness campaigns by biopharmaceutical companies.Human vaccines & immunotherapeutics · 2022Article
- Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards.BMC public health · 2018Article
- Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder.BMC health services research · 2018Article
- Preparing for the arrival of "pink Viagra": strengthening Canadian direct-to-consumer information regulations.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Article
- "Can a Company be Bitchy?" Corporate (and Political and Scientific) Social Responsibility.Journal of bioethical inquiry · 2015Article
- Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly's Canadian 40over40 Erectile Dysfunction Campaign.Healthcare policy = Politiques de sante · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Promotion of prescription drugs may appear to be severely limited in some jurisdictions due to restrictions on direct-to-consumer advertising (DTCA). However, in most jurisdictions, strategies exist to raise consumer awareness about prescription drugs, notably through the deployment of direct-to-consumer information (DTCI) campaigns that encourage patients to seek help for particular medical conditions. In Canada, DTCI is presented by industry and regulated by Health Canada as being purely informational activities, but their design and integration in broader promotional campaigns raise very similar ethical concerns as those associated with DTCA. Specifically, DTCI can be an effective means of familiarizing the public with the scope and benefits of a particular prescription drug and so, like DTCA, can promote increased patient-consumer demand and thus a problematic rise in the prescribing and use of medications that may be neither the most appropriate nor the most cost-effective. Yet, with DTCI the industry is playing within the existing rules and regulations set by health regulators. To respond appropriately to this regulatory incoherence, we argue that DTCI should be regulated as a type of direct-to-consumer indirect advertising. Even if the case and specific regulations presented here are Canadian, the implications extend to every country that has a partial or total prohibition on DTCA.
Indexed as
Identifiers
25963773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.